search
Back to results

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Primary Purpose

Cholera

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PXVX0200
Placebo
Sponsored by
Bavarian Nordic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cholera focused on measuring Vaccine, Bacterial disease condition, Cholera

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy Men or women, age 18 to 50 years (inclusive) without significant medical history, physical or clinical lab abnormalities (as per protocol defined ranges)
  • Women of childbearing potential must have negative urine pregnancy test and must be willing to use adequate birth control for 2 months following vaccination and have additional pregnancy tests as indicated
  • Vaccinees must live alone or have no more than two household contacts willing to sign informed consent and participate in the study
  • Household contacts must be healthy (based on medical history) men or women aged 18-65 years (inclusive)

Exclusion Criteria:

  • Healthcare workers who have direct contact with patients who are immunodeficient, are HIV-positive, have unstable medical condition or are under the age of 18
  • Childcare workers who have direct contact with children who are 2 years of age or younger or those employed in the food service industry
  • Resides with HHCs who are under the age of 18 or over the age of 65
  • Has abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months
  • Has known allergy to, or known medical condition that precludes the use of both tetracycline or ciprofloxacin
  • Previously received a licensed or investigational cholera vaccine
  • Has history of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge)
  • Travel to a cholera-endemic area and experienced symptoms consistent with traveler's diarrhea in the previous 5 years
  • Received or plans to receive any other licensed vaccines from 14 days prior to the study vaccination until Day 28
  • Received or plans to receive antibiotics (other than protocol-specified) or chloroquine within 14 days prior to the study vaccination through to Day 28

Sites / Locations

  • University of Kentucky
  • University of Maryland

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

PXVX0200

Arm Description

Outcomes

Primary Outcome Measures

Safety
Safety defined as frequency and severity of vaccine-related reactogenicity events and reported AEs
Immunogenicity
Immunogenicity as defined as rate of seroconversion (4-fold rise) of serum Inaba vibriocidal antibody and initial estimates of between subject variability of vibriocidal antibody response

Secondary Outcome Measures

Kinetics
Kinetics of serum Inaba vibriocidal antibody after 1 oral dose of CVD 103-HgR
Serum anti-cholera toxin (CT) IgG antibody conversion rates
Anti-cholera toxin IgG antibody conversion rates
Fecal shedding
Fecal shedding of CVD 103-HgR by vaccine recipient
Vibriocidal seroconversion and shedding of CVD 103-HgR in household contacts
Vibriocidal seroconversion and shedding of CVD 103-HgR in household contacts

Full Information

First Posted
April 23, 2012
Last Updated
June 26, 2023
Sponsor
Bavarian Nordic
Collaborators
Emergent BioSolutions
search

1. Study Identification

Unique Protocol Identification Number
NCT01585181
Brief Title
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
Official Title
A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bavarian Nordic
Collaborators
Emergent BioSolutions

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the safety and immunogenicity of a single dose of the PXVX0200 live cholera vaccine versus placebo in volunteers (Vaccinees) and whether PXVX0200, which is a live attenuated bacteria, can be transmitted to other adults living in the same household.
Detailed Description
Approximately 60 subjects and up to 120 household contacts will be enrolled in the United States. Vaccinees will be randomly assigned to receive either PXVX0200 or placebo in a 5:1 ratio and will be followed for 180 days postdose.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholera
Keywords
Vaccine, Bacterial disease condition, Cholera

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
66 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
PXVX0200
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
PXVX0200
Intervention Description
Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Approx 2 grams of lactose reconstituted in water
Primary Outcome Measure Information:
Title
Safety
Description
Safety defined as frequency and severity of vaccine-related reactogenicity events and reported AEs
Time Frame
Day 0-180
Title
Immunogenicity
Description
Immunogenicity as defined as rate of seroconversion (4-fold rise) of serum Inaba vibriocidal antibody and initial estimates of between subject variability of vibriocidal antibody response
Time Frame
Day 0-28
Secondary Outcome Measure Information:
Title
Kinetics
Description
Kinetics of serum Inaba vibriocidal antibody after 1 oral dose of CVD 103-HgR
Time Frame
Day 0-28
Title
Serum anti-cholera toxin (CT) IgG antibody conversion rates
Description
Anti-cholera toxin IgG antibody conversion rates
Time Frame
Day 0-28
Title
Fecal shedding
Description
Fecal shedding of CVD 103-HgR by vaccine recipient
Time Frame
Day 0-7
Title
Vibriocidal seroconversion and shedding of CVD 103-HgR in household contacts
Description
Vibriocidal seroconversion and shedding of CVD 103-HgR in household contacts
Time Frame
Day 0-28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Men or women, age 18 to 50 years (inclusive) without significant medical history, physical or clinical lab abnormalities (as per protocol defined ranges) Women of childbearing potential must have negative urine pregnancy test and must be willing to use adequate birth control for 2 months following vaccination and have additional pregnancy tests as indicated Vaccinees must live alone or have no more than two household contacts willing to sign informed consent and participate in the study Household contacts must be healthy (based on medical history) men or women aged 18-65 years (inclusive) Exclusion Criteria: Healthcare workers who have direct contact with patients who are immunodeficient, are HIV-positive, have unstable medical condition or are under the age of 18 Childcare workers who have direct contact with children who are 2 years of age or younger or those employed in the food service industry Resides with HHCs who are under the age of 18 or over the age of 65 Has abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months Has known allergy to, or known medical condition that precludes the use of both tetracycline or ciprofloxacin Previously received a licensed or investigational cholera vaccine Has history of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge) Travel to a cholera-endemic area and experienced symptoms consistent with traveler's diarrhea in the previous 5 years Received or plans to receive any other licensed vaccines from 14 days prior to the study vaccination until Day 28 Received or plans to receive antibiotics (other than protocol-specified) or chloroquine within 14 days prior to the study vaccination through to Day 28
Facility Information:
Facility Name
University of Kentucky
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536-0084
Country
United States
Facility Name
University of Maryland
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24173028
Citation
Chen WH, Greenberg RN, Pasetti MF, Livio S, Lock M, Gurwith M, Levine MM. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin Vaccine Immunol. 2014 Jan;21(1):66-73. doi: 10.1128/CVI.00601-13. Epub 2013 Oct 30.
Results Reference
derived
Links:
URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910924/
Description
PubMed (results)

Learn more about this trial

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

We'll reach out to this number within 24 hrs